Skip to main content
. 2020 Dec 20;3(2):100224. doi: 10.1016/j.jhepr.2020.100224

Fig. 1.

Fig. 1

Chemotherapy hindered anti-PD-L1 efficacy by inhibiting infiltration of immune effector cells. (A-C) Dose-response curves of 5-FU from RIL-175 and Hepa1-6 murine hepatoma cell lines. (D) Apoptotic event was determined by Annexin-V/ 7-AAD co-staining with one-way ANOVA test. (E) Orthotopic HCC model was established by intrahepatic injection of RIL-175 cells, followed by 5-FU (20 mg/kg), anti-PD-L1 (10 mg/kg) or combined treatment. Tumor growth was monitored by in vivo imaging as shown. (F) Average luciferase intensity at each time point was calculated (n >6 per group) and analysed by two-way ANOVA. (G, H) Endpoint tumor weight was measured with images displaying tumor morphology. (I) Percentage of apoptotic CD45- tumor cells under drug treatment was determined with one-way ANOVA. (J) Correlation between tumor weight and percentage of apoptotic tumor cells were denoted using Pearson correlation coefficient test. (K, L) Proportions of CD8+ T cells and NK cells in overall CD45+ leukocytes were measured in tumor. (M-P) Percentages of tumor immune effector cells were positively correlated with the percentage of apoptotic CD45- tumor cells and negatively associated with tumor weight. ∗p <0.05; ∗∗p <0.01; ∗∗∗p <0.001; ∗∗∗∗p <0.0001. 5-FU, fluorouracil; HCC, hepatocellular carcinoma; NK, natural killer; PD-L1, programmed cell death ligand 1.